Stockpolly
Search
LKFT · NASDAQ · Biotechnology

Lakefront Biotherapeutics (LKFT)

Develops and acquires autoimmune T-cell engager medicines with Gilead.

$28.99
Pre-market+0.17 (+0.61%)
At close$28.82(+0.93%)
Watchlist

In millions of USD, except per-share figures · converted from EUR at the latest rate

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue−243739070888776831,046814
Cost of revenue98−303105108131165131640
Gross profit−145376−14−39−437170701,0462−26
−2604143024292551371181647624
Research & development828485108113212111861253630
603638344651225434127
Selling & marketing9635485−45−333
General & administrative363334303846264973823
Other expenses−402294−94−118−130−84−2136−1−32
Operating income−80−38−44−63−94−184−66−48881−74−51
8654961173−55−209289053
Interest income32292824221512001614
Other non-operating income−40000051−51230−900
Income before tax−72275−5723−182−121−257909162
Income tax expense−3−1−1−10−20−20100
Net income from continuing operations183275−5522−179−121−237909162
Discontinued operations0775−271−22010
Net income18310510−5929−178−123−235908172
EPS, basic−$1.02$0.42$0.08−$0.86$0.34−$2.71−$1.86−$3.57$13.78$0.26$0.03
EPS, diluted−$1.02$0.42$0.08−$0.86$0.34−$2.71−$1.86−$3.57$13.78$0.26$0.03
Weighted average shares, basic1792531276887666666666674
Weighted average shares, diluted06666660666666666667
EBITDA−41−50−53−71−94−184−117365116−41
Depreciation & amortization3670000000010
EBIT−77−50−53−71−94−184−117365116−51